Asked by: Heidi Allen (Liberal Democrat - South Cambridgeshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what progress he has made on the (a) negotiations for NHS access to and (b) appraisal of Ocrelizumab as a treatment for primary progressive MS.
Answered by Seema Kennedy
The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing authoritative, evidence-based guidance for the National Health Service on whether drugs and other treatments represent an effective use of NHS resources.
NICE is currently developing technology appraisal guidance on the use of ocrelizumab for treating primary progressive multiple sclerosis, with final guidance expected in June 2019. NHS England and Roche have now reached a commercial agreement and on 9 May NICE published final draft guidance which recommended ocrelizumab within its marketing authorisation, as an option for treating early primary progressive multiple sclerosis with imaging features characteristic of inflammatory activity in adults. Ocrelizumab will now be routinely available for eligible adults.
Asked by: Heidi Allen (Liberal Democrat - South Cambridgeshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department has taken to support Care Commissioning Groups that experience a disproportionate level of population growth.
Answered by Stephen Hammond
NHS England is responsible for decisions on the weighted capitation formula used to allocate resources between clinical commissioning groups (CCGs). This process is independent of Government. NHS England take advice from the Advisory Committee on Resource Allocation (ACRA), a group of academics and other experts.
ACRA has recommended a new approach to health inequalities which was reflected in the CCG allocations published on 10 January 2019.
Population figures for all programme allocations are based on general practitioner registered list sizes, as they have been since 2013-14. Increases for future years are based on the Office for National Statistics estimates of population trends for resident populations, which is the only consistent and robust national data set available to use for this purpose.
Full details of the CCG allocations announcements for 2019-20 to 2023-24 can be found at the following link:
https://www.england.nhs.uk/allocations/